论文部分内容阅读
目的:探讨EpCAM、Vimentin和N-Cadherin在三阴型乳腺癌(TNBC)中表达的临床病理及预后意义。方法:采用免疫组化Max Vision TM法检测161例TNBC中EpCAM、Vimentin和N-Cadherin表达,分析其与临床病理特征和预后的关系。结果:EpCAM、Vimentin及N-Cadherin在161例TNBC中的表达率分别为62.1%、20.5%、17.4%。EpCAM表达与Vimentin、N-Cadherin均具有正相关性。EpCAM和Vimentin蛋白阳性率均随着肿瘤体积增大、淋巴结阳性、TNM分期增高而增高(均为P<0.05);N-Cadherin表达率随着TNM分期增高而增高(P=0.000)。Log-rank检验和单因素分析显示,EpCAM、Vimentin和N-Cadherin阳性的患者预后较差(均为P<0.001)。多因素COX分析显示,当仅经临床分期、肿瘤大小和淋巴结转移校正时,EpCAM是独立的预后因子(P=0.026),但纳入Vimentin和N-Cadherin后,EpCAM则不是独立的预后因子(P>0.05)。结论:EpCAM在TNBC中与其临床病理特征和预后相关,并与EMT关系密切,EpCAM与EMT可能参与TNBC的发生发展过程。
Objective: To investigate the clinicopathological and prognostic significance of EpCAM, Vimentin and N-Cadherin expression in triple negative breast cancer (TNBC). Methods: The expressions of EpCAM, Vimentin and N-Cadherin in 161 cases of TNBC were detected by immunohistochemistry Max Vision TM method, and their relationship with clinicopathological features and prognosis was analyzed. Results: The expression rates of EpCAM, Vimentin and N-Cadherin in 161 cases of TNBC were 62.1%, 20.5% and 17.4% respectively. EpCAM expression was positively correlated with Vimentin and N-Cadherin. The positive rates of EpCAM and Vimentin were all increased with tumor volume, lymph node positive and TNM stage (all P <0.05). The expression of N-Cadherin increased with TNM staging (P = 0.000). Log-rank test and univariate analysis showed that the patients with positive EpCAM, Vimentin and N-Cadherin had poor prognosis (all P <0.001). In a multivariate COX analysis, EpCAM was an independent prognostic factor (P = 0.026) when clinical stage, tumor size, and lymph node metastases were only corrected, but EpCAM was not an independent prognostic factor when Vimentin and N-Cadherin were included (P > 0.05). Conclusion: EpCAM is correlated with clinicopathological features and prognosis in TNBC and closely related to EMT. EpCAM and EMT may be involved in the development and progression of TNBC.